Clinical Trial

Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

Study acronym: LuTectomy
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP) undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-06-10; most recent amendment 2024-11-07.
Status change: Recruiting → Active, Not Recruiting 2022-05-09
Status change: Not Yet Recruiting → Recruiting 2020-08-05
Trial Details
NCT Number NCT04430192
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: Movember Foundation, Medical Research Future Fund, Endocyte, E.J. Whitten Foundation Prostate Cancer Research Centre
Conditions Prostatic Neoplasms
Enrollment 20 participants
Start Date 2020-08-06
Primary Completion 2022-12-22 (estimated)
Study Completion 2025-08-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-08